SEARCH

SEARCH BY CITATION

References

  • Akileswaran C, Lurie MN, Flanigan TP & Mayer KH (2005) Lessons learned from use of highly active antiretroviral therapy in Africa. Clinical Infectious Diseases 41, 376385.
  • Bekker LG, Orrell C, Reader L et al. (2003) Antiretroviral therapy in a community clinic--early lessons from a pilot project. South African Medical Journal 93, 458462.
  • Bourgeois A, Laurent C, Mougnutou R et al. (2005) Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antiviral Therapy 10, 335341.
  • Braitstein P, Brinkhof MW, Dabis F et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817824.
  • Coetzee D, Boulle A, Hildebrand K, Asselman V, Van CutsemG & Goemaere E (2004a) Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 18(Suppl. 3), S27S31.
  • Coetzee D, Hildebrand K, Boulle A et al. (2004b) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887895.
  • Crane JT, Kawuma A, Oyugi JH et al. (2006) The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS and Behavior 10, 437442.
  • Crum NF, Riffenburgh RH, Wegner S et al. (2006) Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. Journal of Acquired Immune Deficiency Syndromes 41, 194200.
  • Dabis F, Balestre E, Braitstein P et al. (2005) Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology 34, 979986.
  • Djomand G, Roels T, Ellerbrock T et al. (2003) Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS 17(Suppl. 3), S5S15.
  • Egger M (2007) Outcomes of Antiretroviral Treatment in Resource Limited and Industrialized Countries. Presented on the 14th Conference on Retroviruses and Opportunistic Infections, 25–28th February 2007, LA, USA.
  • Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119129.
  • Etard JF, Ndiaye I, Thierry-Mieg M et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20, 11811189.
  • Fawzi WW, Msamanga GI, Spiegelman D et al. (2004) A randomized trial of multivitamin supplements and HIV disease progression and mortality. The New England Journal of Medicine 351, 2332.
  • Ferradini L, Laureillard D, Prak N et al. (2007) Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 21, 22932301.
  • Grabar S, Le Moing V, Goujard C et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Annals of Internal Medicine 133, 401410.
  • Hogg RS, Yip B, Kully C et al. (1999) Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal 160, 659665.
  • Ivers LC, Kendrick D & Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases 41, 217224.
  • Kabugo C, Bahendeka S, Mwebaze R et al. (2005) Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. Journal of Acquired Immune Deficiency Syndromes 38, 578583.
  • Kheang ST (2006) Antiretroviral treatment in the chronic disease clinics in Cambodia: an MSF experience. Thesis: Master of Science in Disease Control, Institute of Tropical Medicine, Antwerp
  • Kremer H & Sonnenberg-Schwan U (2003) Women living with HIV Does Sex and Gender Matter? A Current Literature Review. European Journal of Medical Research 8, 816.
  • Laniece I, Ciss M, Desclaux A et al. (2003) Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 17(Suppl. 3), S103S108.
  • Laurent C, Diakhate N, Gueye NF et al. (2002) The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16, 13631370.
  • Laurent C, Kouanfack C, Koulla-Shiro SA et al. (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364, 2934.
  • Laurent C, Ngom Gueye NF, Ndour CT et al. (2005a) Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. Journal of Acquired Immune Deficiency Syndromes 38, 1417.
  • Laurent C, Meilo H, Guiard-Schmid JB et al. (2005b) Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clinical Infectious Diseases 41, 108111.
  • Laurent C, Kouanfack C, Vergne L et al. (2006) Antiretroviral drug resistance and routine therapy, Cameroon. Emerging Infectious Diseases 12, 10011004.
  • Laurent C, Kouanfack C, Koulla-Shiro S et al. (2007) Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS 21, 768771.
  • Lawn SD, Myer L, Orrell C, Bekker LG & Wood R (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19, 21412148.
  • Mannheimer SB, Morse E, Matts JP et al. (2006) Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes 43(Suppl. 1), S41S47.
  • Moore AL, Sabin CA, Johnson MA & Phillips AN (2002) Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. Journal of Acquired Immune Deficiency Syndromes 29, 197202.
  • Mosoko JJ & Affana G (2005) Prévalence du VIH et facteurs associés. In: Enquête Démographique et de Santé du Cameroun 2004, Chapître 16 (ed Calverton, MD, USA: INS et ORC Macro) DHS, Cameroon, pp. 293314.
  • Nicastri E, Angeletti C, Palmisano L et al. (2005) Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19, 577583.
  • OMS & ONUSIDA (2006) Elargissement de l’accès au traitement antirétroviral dans le monde. Rapport sur l’initiative “3 millions d’ici 2005” et au-delà.
  • Oyugi JH, Byakika-Tusiime J, Ragland K et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21, 965971.
  • Perez-Hoyos S, Del Amo J, Muga R et al. (2003) Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17, 353359.
  • Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB & Freedberg KA (2007) Predictors of antiretroviral treatment failure in an urban HIV clinic. Journal of Acquired Immune Deficiency Syndromes 44, 3037.
  • Rosen S, Fox MP & Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. Public Library of Science Medicine 4, e298.
  • Schneider M, Zwahlen M & Egger M (2004) Natural History and Mortality in HIV-Positive Individuals Living in Resource-Poor Settings: A Literature Review. UNAIDS, Geneva (Obligation HQ/03/463871).
  • Severe P, Leger P, Charles M et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. New England Journal of Medicine 353, 23252334.
  • Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB & Quinn TC (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New England Journal of Medicine 344, 720725.
  • Sterne JA, Hernan MA, Ledergerber B et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366, 378384.
  • Stevens G, Rekhviashvili N, Scott LE, Gonin R & Stevens W (2005) Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. Journal of Clinical Microbiology 43, 857861.
  • Tassie JM, Szumilin E, Calmy A & Goemaere E (2003) Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 17, 19951997.
  • Van Vaerenbergh K, Harrer T, Schmit JC et al. (2002) Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Research and Human Retroviruses 18, 419426.
  • Weidle PJ, Malamba S, Mwebaze R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet 360, 3440.
  • Weidle PJ, Wamai N, Solberg P et al. (2006) Adherence to antiretro viral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368, 15871594.
  • World Health Organization (2003) Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. WHO, Geneva. Available at: http://www.who.int/3by5/publications/documents/arvguidelines/en/.
  • World Health Organization (2006) Towards Universal Access by 2010: How WHO is Working with Countries to Scale-up HIV Prevention, Treatment, Care and Support. WHO, Geneva. Available at: http://www.who.int/hiv/topics/universalaccess/en/index.html.
  • Zachariah R, Fitzgerald M, Massaquoi M et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20, 23552360.